Sun Pharma, India’s largest drugmaker, announced Sunday it will buy New Jersey-based Organon & Co in a fully cash-funded deal worth $11.75 billion including debt. The offer price is $14.00 per share.
Sun Pharma agreed to acquire New York-listed women’s health-care company Organon, in what is likely to be one of the biggest India outbound deals in years https://t.co/30lkj6q6rR
— Bloomberg (@business) April 27, 2026
Organon stock had already jumped nearly 31% on Friday after the Economic Times first reported that Sun Pharma was in talks to buy the company for around $13 billion. When the deal was officially confirmed Sunday, Organon rose a further ~15% in early Monday premarket trading.
The total move over the two sessions puts the stock up roughly 46% from where it was trading before news of the deal broke.
Organon was spun off from Merck in 2021 and focuses on women’s health, biosimilars, and established branded medicines. It reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion for 2025.
Sun Pharma said it plans to fund the deal through a mix of cash and committed bank financing. Both boards have approved the transaction.
The deal gives Sun Pharma access to over 70 products sold across more than 140 countries. It also moves the Indian drugmaker into biosimilars, where the combined company would become the seventh-largest player globally.
Organon’s key markets include the U.S., Europe, China, Canada, and Brazil. It operates six manufacturing facilities across the EU and emerging markets.
Macquarie analyst Dr. Kunal called the deal “strategically and financially compelling” for Sun. He noted that the combined entity will have 27% of revenue from innovative medicines, up from 20% for Sun Pharma alone.
Sun Pharma currently operates in dermatology, ophthalmology, and onco-dermatology on the innovative medicines side. Adding Organon’s women’s health portfolio would expand that footprint considerably.
The merged company would also become a top-three player in global women’s health.
Organon came into this deal carrying $8.6 billion in debt and a cash balance of $574 million as of December 2025. Its net debt to EBITDA ratio stood at 4 times going into the deal.
Sun Pharma, by contrast, was in a net positive position before the acquisition. After closing, the combined entity is projected to carry a net debt to EBITDA ratio of 2.3 times.
Bhavesh Shah of Equirus Capital noted that deals like this can be “value accretive over the medium to long term,” but flagged near-term risks including integration costs and execution challenges.
This is the sixth acquisition Sun Pharma has made in the last 16 years. Past deals include a 2007 takeover of distressed Israeli firm Taro Pharma and a 2014 acquisition of Ranbaxy Laboratories for roughly $3.2 billion.
The Organon deal is expected to lift Sun Pharma into the top 25 global pharmaceutical companies, with combined pro forma revenue of $12.4 billion.
The transaction is expected to close in early 2027, subject to regulatory and shareholder approvals.
The post Organon (OGN) Stock Surges 46% as Sun Pharma Agrees to $11.75B Takeover Deal appeared first on CoinCentral.
